Hemex Health has announced an innovative measurement capability for clinicians monitoring sickle cell disease therapy.


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
In a clinical study conducted at the pediatric SCD Clinic of Korle Bu Teaching Hospital in Accra, Ghana, Gazelle’s Hb F quantification results were within 4.5% of HPLC Hb F results (the gold standard) with a 95% confidence range.

PORTLAND, Ore., and MUMBAI, India, May 8, 2022,  Hemex Health, a health-tech startup based in Portland, Oregon, has announced a significant enhancement to their GazelleTM Hb Variant test, which allows for more precise measurements of Hb F, also known as fetal hemoglobin. The improved accuracy could be useful for monitoring hydroxyurea therapy in point-of-care settings. 

 

The software update comes only months after the business announced that its Hb Variant test can now detect beta-thalassemia illness and trait in addition to sickle cell disease (SCD) and trait.

 

In a clinical study conducted at the pediatric SCD Clinic of Korle Bu Teaching Hospital in Accra, Ghana, Gazelle’s Hb F quantification results were within 4.5% of HPLC Hb F results (the gold standard) with a 95% confidence range. The results of this study will be presented at an international conference this June and will also be published in a peer-reviewed journal later this year.

 

Since the 1980s, hydroxyurea has been used to treat adult sickle cell disease patients, and the US Food and Drug Administration has licensed it for use in children. The medicine has been demonstrated to enhance Hb F production in patients, resulting in fewer pain crises and hospital admissions, according to the National Institutes of Health's National Library of Medicine publication. In India, Africa, and the Middle East, hydroxyurea is becoming more popular. "Tracking variations in Hb F levels over time is part of the monitoring strategy for patients on hydroxyurea," said Dr. Catherine Segbefia of Ghana's Korle Bu Teaching Hospital.   

 

"Having this capacity at the time of treatment with Gazelle's Hb Variant test will increase access to this therapy, especially for those living in rural areas," the business claims.

 

Tags : #celldisease #therapy #healthclinic #smitakumar #medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Smart Operating Rooms: The Future of Hospital OTNovember 21, 2026
Smartphone Diagnostics: Phones as Medical Screening ToolsNovember 21, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026